Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
As its high-margin compounded GLP-1 business evolves, Hims & Hers Health may be finding a new opportunity in peptides.
Shares of the telehealth company jumped Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. announced Wednesda… [3473 chars]
Source: CNBC | Published: 2026-04-16T17:44:50Z
Credit: CNBC
